Last reviewed · How we verify
NCT05525065
Investigating the Morbidity of Glucocorticoid Use in Patients With Autoimmune Bullous Diseases (AIBDs)
trial testing GlucoCorticoid in Autoimmune Bullous Dermatosis in 138 participants. Status unknown.
1 September 2023
Quick facts
| Lead sponsor | Premier Specialists, Australia |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 138 |
| Start date | 2 February 2019 |
| Primary completion | 1 September 2023 |
| Estimated completion | 1 September 2025 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- GlucoCorticoid — full drug profile →
Conditions studied
- Autoimmune Bullous Dermatosis — all drugs for Autoimmune Bullous Dermatosis →
- Glucocorticoids Toxicity — all drugs for Glucocorticoids Toxicity →
Sponsor
Premier Specialists, Australia — full company profile →
Who can join
18 and older, any sex, with Autoimmune Bullous Dermatosis or Glucocorticoids Toxicity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project utilised the validated glucocorticoid toxicity index (GTI) tool to assess the morbidity of glucocorticoid-use in patients with autoimmune bullous disease. In particular, the study investigated the nature and prevalence of glucocorticoid-induced myopathy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05525065
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of GlucoCorticoid
Trials testing the same drug.
- NCT06047171 — Rescue of Nephrons With ALE.F02 (RENAL-F02) · Phase 2 · recruiting
- NCT05969522 — Stratified Therapy on Pediatric AAGN · Phase 4 · unknown
- NCT04499196 — Glucocorticoids and Pulmonary Hypertension · unknown
- NCT02997605 — Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients · Phase 4 · completed
Other Premier Specialists, Australia trials
Trials by the same sponsor.
- NCT06032078 — Evaluation of the Responsiveness of Investigator Global Assessment Score for Keratosis Pilaris · NA · unknown
- NCT05534776 — Validation of 5-Point Investigator Global Assessments for Pemphigus · unknown
- NCT05535517 — Development and Validation of an Investigator Global Assessment Score for Keratosis Pilaris · unknown
- NCT04971200 — Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo · EARLY_PHASE1 · completed
- NCT07228481 — Study of Two Dosages of Roaccutane in Cystic Acne · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05525065 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Premier Specialists, Australia
- Last refreshed: 31 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05525065.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing